Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Amdocs stock
Learn how to easily invest in Amdocs stock.
Amdocs Ltd is a software-infrastructure business based in the US. Amdocs shares (DOX) are listed on the NASDAQ and all prices are listed in US Dollars. Amdocs employs 30,000 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Amdocs
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – DOX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Amdocs stock price (NASDAQ: DOX)Use our graph to track the performance of DOX stocks over time.
Amdocs shares at a glance
|Latest market close||$84.45|
|52-week range||$67.36 - $87.76|
|50-day moving average||$82.36|
|200-day moving average||$78.48|
|Wall St. target price||$90.50|
|Dividend yield||$1.475 (1.9%)|
|Earnings per share (TTM)||$4.47|
Buy Amdocs shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Amdocs stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Amdocs price performance over time
|1 week (2022-06-28)||1.34%|
|1 month (2022-06-03)||-2.86%|
|3 months (2022-04-01)||N/A|
|6 months (2022-01-05)||13.36%|
|1 year (2021-07-02)||7.72%|
|2 years (2020-07-02)||40.70%|
|3 years (2019-07-05)||34.39%|
|5 years (2017-07-03)||31.28%|
Is Amdocs stock undervalued or overvalued?
Valuing Amdocs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amdocs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amdocs's P/E ratio
Amdocs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Amdocs shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Amdocs's PEG ratio
Amdocs's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0911. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amdocs's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amdocs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $841.6 million.
The EBITDA is a measure of a Amdocs's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$4.4 billion|
|Operating margin TTM||14.38%|
|Gross profit TTM||$1.5 billion|
|Return on assets TTM||6.01%|
|Return on equity TTM||15.5%|
|Market capitalisation||$10.4 billion|
TTM: trailing 12 months
Amdocs's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amdocs.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Amdocs's total ESG risk score
Total ESG risk: 20.97
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amdocs's overall score of 20.97 (as at 12/31/2018) is pretty good – landing it in it in the 21st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Amdocs is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Amdocs's environmental score
Environmental score: 6.71/100
Amdocs's environmental score of 6.71 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Amdocs is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Amdocs's social score
Social score: 15.33/100
Amdocs's social score of 15.33 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Amdocs is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Amdocs's governance score
Governance score: 10.44/100
Amdocs's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Amdocs is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Amdocs's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Amdocs scored a 1 out of 5 for controversy – the highest score possible, reflecting that Amdocs has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||20.97|
|Total ESG percentile||20.5|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||1|
Amdocs share dividends
Dividend payout ratio: 28.76% of net profits
Recently Amdocs has paid out, on average, around 28.76% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.9% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amdocs shareholders could enjoy a 1.9% return on their shares, in the form of dividend payments. In Amdocs's case, that would currently equate to about $1.475 per share.
While Amdocs's payout ratio might seem fairly standard, it's worth remembering that Amdocs may be investing much of the rest of its net profits in future growth.
Amdocs's most recent dividend payout was on 28 July 2022. The latest dividend was paid out to all shareholders who bought their shares by 28 June 2022 (the "ex-dividend date").
Amdocs share price volatility
Over the last 12 months, Amdocs's shares have ranged in value from as little as $67.3641 up to $87.758. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amdocs's is 0.711. This would suggest that Amdocs's shares are less volatile than average (for this exchange).
Amdocs Limited, through its subsidiaries, provides software and services worldwide. The company designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. It provides CES21, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; the Commerce and Care suite for order capture, handling, and customer engagement; the Monetization suite for charging, billing, policy, and revenue management; Intelligent Networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; MarketONE, a cloud-native business ecosystem; Digital Brands Suite, a pre-integrated digital business suite for digital telecom brands and small-scale service providers; and eSIM Cloud for service providers. It also offers AI-powered, cloud-native, and home operating systems; data intelligence solutions and applications; media services for media publishers, TV networks, and video streaming and service providers; end-to-end application development and maintenance services; and ongoing services. In addition, the company provides a line of services designed for various stages of a service provider's lifecycle includes design, delivery, quality engineering, operations, systems integration, mobile network services, consulting, and content services; managed services comprising application development, modernization and maintenance, IT and infrastructure services, testing and professional services that are designed to assist customers in the selection, implementation, operation, management, and maintenance of IT systems. It serves to the communications, cable and satellite, entertainment, and media industry service providers, as well as mobile virtual network operators and directory publishers. Amdocs Limited was founded in 1988 and is headquartered in Saint Louis, Missouri.
Amdocs in the news
Amdocs (DOX) & Unicard to Offer Integrated Ticketing Solution
Vishay (VSH) Boosts Passive Component Portfolio With New Product
Unicard and Amdocs Collaborate to Deliver Integrated Multi-Modal Ticketing for Public Transport Users
Frequently asked questionsWhat percentage of Amdocs is owned by insiders or institutions?
Currently 0.058% of Amdocs shares are held by insiders and 98.492% by institutions. How many people work for Amdocs?
Latest data suggests 30,000 work at Amdocs. When does the fiscal year end for Amdocs?
Amdocs's fiscal year ends in September. Where is Amdocs based?
Amdocs's address is: 625 Maryville Centre Drive, Saint Louis, MO, United States, 63141 What is Amdocs's ISIN number?
Amdocs's international securities identification number is: GB0022569080 What is Amdocs's CUSIP number?
Amdocs's Committee on Uniform Securities Identification Procedures number is: G02602103
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert